CliffBio
small molecule

IRBESARTAN

IRBESARTAN

Loss of exclusivity—loss of exclusivity
CompanyLupin →See this company's full patent-cliff portfolio

Drug detail

Brand nameIRBESARTAN
Active ingredientIRBESARTAN
Strength75MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalOctober 2012
Marketing statusDISCN

More from Lupin

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.